Salvage Chemotherapy with Mitomycin, Docetaxel, and Irinotecan (MDI Regimen) in Metastatic Pancreatic Adenocarcinoma: A Phase I and II Trial

References

• Villalona-Calero M. A., Kolesar J. M. Mitomycin as a modulator of irinotecan anticancer activity. Oncology 2002; 16: 21–25
   PubMed Web of Science ®Google Scholar
• Bleiberg H. CPT-11 in gastrointestinal cancer. Eur. J. Cancer 1999; 35: 371–379, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wagener D. J., Verdonk H. E., Dirix L. Y., Catimel G., Siegenthaler P., Buitenhuis M., Mathieu-Boue A., Verweij J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol. 1995; 6: 129–132, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Androulakis N., Kourousis C., Dimopoulos M. A., Samelis G., Kakolyris S., Tsavaris N., Genatas K., Aravantinos G., Papadimitriou C., Karabekios S., Stathopoulos G. P., Georgoulias V. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J. Clin. Oncol. 1999; 17: 1779–1785, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rougier P., Adenis A., Ducreux M., de Forni M., Bonneterre J., Dembak M., Clouet P., Lebecq A., Baille P., Lefresne-Soulas F., Blanc C., Armand J. P. A phase II study : docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer 2000; 36: 1016–1025, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Okada S., Sakata Y., Matsuno S., Kurihara M., Sasaki Y., Ohashi Y., Taguchi T., Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br. J. Cancer 1999; 80: 438, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gil-Delgado M. A., Antoine E. C., Guinet F., Bassot V., Grapin J. P., Benhammonda A., Adam R., Castaing D., Bismuth H., Kayat D. Phase I–II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer. Am. J. Clin. Oncol. 2001; 24: 251–254, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Scheitauer W., Kornek G. V., Brugger S., Ullrich-Pur H., Valencak J., Raderer M., Fiebiger W., Kovats E., Lang F., Depisch D. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest. 2002; 20: 60–68, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yamao T., Shirao K., Matsumura Y., Muro K., Yamada Y., Goto M., Chin K., Shimada Y. Phase I–II study of irinotecan combined with mitomycin C in patients with advanced gastric cancer. Ann. Oncol. 2001; 12: 1729–1735, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fuchs C. S., Lynch T. J., Earle C. C., Enzinger P. C., Kulke M. H., Vincitore M., Seiden M. V., Ryan D. P., Mayer R. J., Clark J. W. (2001) Phase I Trial of Taxotere, Cisplatin, and CPT-11 (TPC) in Advanced Solid Tumor Malignancies. Proceedings of the American Society of Clinical Oncology, San Francisco, CA, May, 12–152001, S. M. Grunberg. American Society of Clinical Oncology, San Francisco, CA, 2087
   Google Scholar
• Rich R. S., Burtness B., Blum K., Gallipoli M., McKeon A., Peccerillo J., Murren J. (2001) Dose Escalation Trial of Irinotecan Plus Docetaxel in Patients with Advanced Cancer. Proceedings of the American Society of Clinical Oncology, San Francisco, CA, May, 12–152001, S. M. Grunberg. American Society of Clinical Oncology, San Francisco, CA, 2130
   Google Scholar
• Kurtz J., Negrier S., Husseini F., Limacher J., Borel C., Wagner J., Prevot G., Bergerat J., Dufour P. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology 2003; 50: 567–570, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Enrech S., Belon J., Mendez E., Gonzalez E., Quiben R., Ballesteros P., Alfonso P. G., Delgado J., Sancho J., Menendez P., Lopez P., GOTI Study Group (2001) A Phase II Study of Docetaxel in Combination with Irinotecan (CPT-11) in Locally Advanced or Metastatic Gastric Cancer. Proceedings of the American Society of Clinical Oncology, San Francisco, CA, May, 12–152001, S. M. Grunberg. American Society of Clinical Oncology, San Francisco, CA, 2325
   Google Scholar
• Couteau C., Risse M. L., Ducreux M., Lefresne-Soulas F., Riva A., Lebecq A., Ruffie P., Rougier P., Lokiec F., Bruno R., Armand J. P. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J. Clin. Oncol. 2000; 18: 3545–3552, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Adjei A. A., Klein C. E., Kastrissios H., Goldberg R. M., Alberts S. R., Pitot H. C., Sloan J. A., Reid J. M., Hanson L. J., Atherton P., Rubin J., Erlichman C. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J. Clin. Oncol. 2000; 18: 1116–1123, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Masuda N., Negoro S., Kudoh S., Sugiura T., Nakagawa K., Saka H., Takada M., Niitani H., Fukuoka M. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small cell lung cancer. J. Clin. Oncol. 2000; 8: 2996–3003
   Google Scholar
• Knuuttila A., Ollikainen T., Halme M., Mali P., Kivisaari L., Linnainmaa K., Jekunen A., Mattson K. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma—a feasibility study. Anticancer Drugs 2000; 11: 257–261, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Font A., Sanchez J. M., Rosell R., Taron M., Martinez E., Guillot M., Manzano J. L., Margeli M., Barnadas A., Abad A. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer 2002; 37: 213–218, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bleickardt E., Argiris A., Rich R., Blum K., McKeon A., Tara H., Zelterman D., Burtness B., Davies M. J., Murren J. R. Phase I dose-escalation trial of docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol. Ther. 2002; 1: 646–650, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Negoro S., Nishioka M., Nakagawa K., Takada M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 1992; 10: 1225–1229, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Burris H. A., Erland J. B., Thomas M., Greco F. A. Phase I trial of docetaxel administered by weekly infusion with advanced refractory cancer. J. Clin. Oncol. 1998; 16: 2164–2219, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ajani J. A., Welch S. R., Raber M. N., Fields W. S., Krakoff I. H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8: 147–159, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989; 10: 1–10, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Kaplan E. L., Meier P. Non-parametric estimations from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481, [CSA]
   Web of Science ®Google Scholar
• Reni M., Passoni P., Panucci M. G., Nicoletti R., Galli L., Balzano G., Zerbi A., Di Carlo V., Villa E. Definitive results of a phase II trial of Pef-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J. Clin. Oncol. 2001; 19: 2679–2686, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Palmer K., Kerr M., Knowles G., Cull A., Carter D. C., Leonard R. C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. 1994; 81: 882–885, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Glimelius B., Hoffmann K., Sjoeden P. O., Jacobsson G., Sellstrom H., Enander L. K., Linne T., Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996; 7: 593–600, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Maisey N., Chau I., Cunningham D., Norman A., Seymour M., Hickish T., Iveson T., O'Brien M., Tebbutt N., Harrington A., Hill M. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J. Clin. Oncol. 2002; 20: 3130–3136, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Berlin J. D., Catalano P., Thomas J. P., Kugler J. W., Haller D. G., Benson A. B., III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002; 20: 3270–3275, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ducreux M., Rougier P., Pignon J.-P., Douillard J.-Y., Seitz J.-F., Bugat R., Bosset J. F., Merouche Y., Raoul J. L., Ychou M., Adenis A., Berthault-Cvitkovic F., Luboinski M. Groupe Digestif of the Federation Nationale des Centres de Lutte Contre le Cancer Digestif. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. 2002; 13: 1185–1191, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar